Drugs / Platelet rich fibrin matrix
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00956020 | Oct 2009 → Feb 2011 | — | The New York Eye & Ear Infirmary | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03616925 | Sep 2013 → Sep 2014 | — | KLE Society's Institute of Dental Sciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00874094 Comparator | Apr 2008 → Jun 2009 | — | The New York Eye & Ear Infirmary | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | platelet-rich fibrin matrix | “OBJECTIVE: To evaluate the histological changes induced in human skin by injection of autologous platelet-rich fibrin matrix (PRFM).” PMID 22006233 ↗ Oct 2011 |
| Known as | PRFM | “Platelet Rich Fibrin Matrix (PRFM) is an autologous biologic material created by two step centrifugation of whole blood without the use of exogenous thrombin.” NCT03616925 ↗1“OBJECTIVE: To evaluate the histological changes induced in human skin by injection of autologous platelet-rich fibrin matrix (PRFM).” PMID 22006233 ↗ Oct 2011 |
| Route | Other | “injected into the deep dermis and immediate subdermis of the upper arms of subjects.” PMID 22006233 ↗ Oct 2011 |